Drugs / HSV529
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02571166 | Nov 2015 → Dec 2018 | herpes simplex type 2 infectious disease | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01915212 | Sep 2013 → Mar 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSV529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02571166 ↗ |
| Modality | Vaccine | “a replication-defective HSV2 vaccine” PMID 31058977 ↗ Aug 2019 |
| Route | Intramuscular | “The vaccine was administered intramuscularly (deltoid muscle)” NCT01915212 ↗ |